Cell Dissociation Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024-2030)

Cell Dissociation Market Size

Cell Dissociation Market Analysis

Enzymatic Dissociation Products Dominate the Industry

The enzymatic dissociation category dominates the market, accounting for a revenue share of over 48% in 2022. This is attributed to its greater efficiency, gentle nature, and widespread use in veterinary medicine, biotechnological processes, and tissue culture lab. Among enzymatic dissociation products, collagenases are widely used because of their large number of applications such as wound healing, burns, glaucoma, debridement, and keloid; presence in several organisms and animal cells; and availability.

In July 2020, the injection of collagenase is approved by the FDA for the treatment of cellulite in adult women. Because of its availability in the form of injection, the market is expanding in this category. Also, collagenase and hyaluronidase are successfully used as isolation enzymes in treating breast cancer. Further, with the rising prevalence of glaucoma, the use of collagenase is also increasing. For instance, in 2022, according to government reports, more than 80 million people suffered from glaucoma and more than 3 million cases were reported only in the U.S.

In addition, the trypsin category is expected to show significant growth during the forecast period. This can be attributed to various reasons such as it is used to treat digestive disorders and helps in protein digestion.

On the other hand, the non-enzymatic category is expected to witness the fastest growth in the coming years. This can be ascribed to the rising demand for non-enzymatic products because of their various advantages, such as non-toxic nature, ready-to-use, and high yield of viable cells during the dissociation process. It also reduces the risk of cellular damage, its components are derived from animals, and has gentle cellular disaggregation.

Furthermore, the instruments and accessories category is expected to show significant growth in the future. This can be due to their efficiency and speed of tissue dissociation at the point of care and controlled shear forces.

Connective Tissue Is the Leading the Category

On the basis of tissue type, connective tissue is leading the category because of the rising prevalence of cancer, which will rise the single cell-based research. For instance, according to government sites, around one in six deaths across the world was due to cancer in 2020. Moreover, it is composed of extracellular fibers and cells and the main component is collagen. The collagenase enzyme is used during the isolation of endothelial, epithelial, or adrenal tissue, and it is also used in the isolation of several cellulite types such as hepatocytes, adipocytes, and cardiomyocytes, and for the treatment of mammary or other soft tissues.

Pharmaceutical & Biotechnology Companies Hold Largest Share

Pharmaceutical and biotechnology companies account for the largest market share because of their rising R&D investments in various therapeutic areas for the introduction of novel drugs. Moreover, investments have also increased in various research activities including efficacy studies, clinical trials, and toxicity studies. These drive the need for dissociation products for the isolation of cells from primary tissues in pharmaceutical and biotechnology organizations.

Over the last few years, opportunities in the biopharmaceuticals sector have been increasing, as a result of the safety and great effectiveness of these drugs. Along with this, they provide several benefits, such as potent action and high effectiveness, have the potential to cure diseases rather than merely treat symptoms, and have fewer side effects, which have contributed to the growing demand for biopharmaceutical products. In addition, the increased spending in R&D activities by biopharmaceutical firms is further propelling the market in this category.

In emerging economies such as China, India, and Brazil, market players are expected to witness significant growth potential in the upcoming years, because of the increasing R&D efforts in these countries in the life sciences sector. For instance, pharmaceutical firms based in India are spending a lot of money on R&D to introduce novel medicines. An Indian pharmaceutical company, Cadila Healthcare Ltd. invested 7–8% of its revenue in R&D in 2021. Similarly, another pharmaceutical business with headquarters in India, Biocon spent USD 85.89 million in R&D in 2022. Thus, the rising investments in R&D by companies in developing countries are expected to fuel the demand for cell dissociation.

Geographical Analysis

North America has the leading position in the cell dissociation market, and it will also hold the same position in the coming years, accounting for a value of USD 552 million in 2030. This is attributed to the surging cases of cancer and glaucoma and the increasing need for biopharmaceutical products. In North America, the U.S. market holds the leading position, and it will grow at a CAGR of over 17.2%, during the forecast period. This can be attributed to the high focus on R&D related to biotechnology.

Moreover, in 2021, approximately 1.9 million cases of cancer were diagnosed and around 608,570 deaths were reported in the U.S., as per government reports. In the U.S., the major cause of cancer is cigarette smoking. Smoking prevalence is higher among Alaskan and American women than men, and about a quarter of people suffering from cancer are regular cigarette smokers. Due to a large number of cancer cases, it became important to study the physiology and anatomy of a single cell. For converting tissue clusters into single cells, dissociation is required because it helps in recovering fully functional units of life with several methods.

Report Breakdown

Based on Product

• Enzymatic Dissociation Products
  • Collagenase
  • Trypsin
  • Papain
  • Elastase
  • DNASE
  • Hyaluronidase 
• Non-Enzymatic Dissociation Products
• Instruments

Based on Tissue

• Connective Tissue
• Epithelial Tissue

Based on End User

• Pharmaceutical and Biotech Companies
• Research and Academic Institutes

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Cell Dissociation Market Share

The major biopharmaceutical companies are focusing on the expansion of R&D in different therapeutic areas, in order to bring new pharmaceutical products. These players have initiated to invest significantly in toxicity studies, clinical trials, and efficacy studies, among others. In order to isolate cells from primary tissues, the majority of the research utilizes dissociation products. For instance, the pharmaceutical sector spent 7.2% of the total revenue on R&D in 2021, and it was evaluated that around 84 novel drug substances were launched, and approximately 6,000 products were in pipeline in 2021.

Additionally, biopharmaceutical companies are also focusing on the advancement of personalized medicine. Also, scientists and researchers are examining novel substances, so as to provide insights into the best medication targets and illuminate illness pathways. Therefore, it is expected that the market is fueled by the increasing R&D activities in the coming years.